Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rogaratinib Continued Treatment Roll-over Study
NCT04125693Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rogaratinib in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma (UC), head and neck cancer (HNC), breast cancer, sponsored by Bayer. Started Oct 2019; status: completed.
02
Drugs
rogaratinib
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)urothelial carcinoma (UC)head and neck cancer (HNC)breast cancer
Beyond the preview
Go deeper on NCT04125693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04125693.